BEAM - Beam Therapeutics Inc.
IEX Last Trade
26.88
0.130 0.484%
Share volume: 9,483
Last Updated: Fri 27 Dec 2024 06:30:07 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
0.40%
PREVIOUS CLOSE
CHG
CHG%
$26.75
0.13
0.49%
Fundamental analysis
12%
Profitability
0%
Dept financing
10%
Liquidity
75%
Performance
10%
Performance
5 Days
0.38%
1 Month
11.49%
3 Months
14.69%
6 Months
15.98%
1 Year
-3.39%
2 Year
-24.34%
Key data
Stock price
$26.88
DAY RANGE
$26.75 - $28.68
52 WEEK RANGE
$21.90 - $49.50
52 WEEK CHANGE
-$2.11
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/06/2024
Company detail
CEO: John Evans
Region: US
Website: beamtx.com
Employees: 510
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: beamtx.com
Employees: 510
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Beam Therapeutics Inc. develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia. It also develops therapies for alpha-1 antitrypsin deficiency; ocular diseases; and other liver, muscle, and central nervous system disorders.
Recent news